326 related articles for article (PubMed ID: 30627896)
1. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
3. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer.
Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
[TBL] [Abstract][Full Text] [Related]
5. Comparative enzyme immunoassay of matrix metalloproteinases-2, -7, -9 and their tissue inhibitor-2 in tumors and plasma of patients with gastric cancer.
Gerstein ES; Sini L; Ryabov AB; Dvorova EK; Yurchenko AA; Stilidi IS; Kushlinskii NE; Davydov MI
Bull Exp Biol Med; 2009 Dec; 148(6):899-902. PubMed ID: 21116502
[TBL] [Abstract][Full Text] [Related]
6. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
[TBL] [Abstract][Full Text] [Related]
7. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
8. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
9. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.
Fuksiewicz M; Kotowicz B; Rutkowski A; Kowalska M
Tumour Biol; 2015 May; 36(5):3629-35. PubMed ID: 25549795
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer.
Mroczko B; Lukaszewicz-Zając M; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2011; 49(1):125-31. PubMed ID: 21526499
[TBL] [Abstract][Full Text] [Related]
11. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
[TBL] [Abstract][Full Text] [Related]
14. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
16. Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration.
Oszajca K; Szemraj M; Szemraj J; Jurowski P
Ophthalmic Genet; 2018 Dec; 39(6):684-698. PubMed ID: 30289322
[TBL] [Abstract][Full Text] [Related]
17. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.
Alakus H; Grass G; Hennecken JK; Bollschweiler E; Schulte C; Drebber U; Baldus SE; Metzger R; Hölscher AH; Mönig SP
Histol Histopathol; 2008 Aug; 23(8):917-23. PubMed ID: 18498066
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
20. Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer.
Zhang M; Teng XD; Guo XX; Li ZG; Han JG; Yao L
Breast; 2013 Jun; 22(3):330-4. PubMed ID: 22995648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
